Infant Bacterial Therapeutics Upcoming Drug Trials

Infant Bacterial Therapeutics intends to develop the pharmaceutical drug candidate IBP-9414 for the prevention of NEC in premature infants.IBP-9414 contains a co-evolved human bacterial strain derived from human breast milkThe active bacteria used in IBP-9414 is known to be anti-inflammatory, anti-pathogenic and beneficial to gut motilityIBP-9414 is formulated for the most convenient and suitable administration to premature infants in hospital NICUIBP-9414 has been granted Orphan Drug Designation for the prevention of NEC by the FDA and by the European Commission

Share This Post...

About The Author: Graham's Foundation

Comments are closed, but trackbacks and pingbacks are open.